Cardio-oncology & otherSecondary analysis
Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease
- Secondary analysis of the INVESTED randomised trial
- prespecified
- immune response substudy
- double-blind
- active-controlled
- 157 sites in the US and Canada
Hemagglutination inhibition assays at randomization and 4 weeks, 2017-2018 and 2018-2019 seasons
Authors' conclusion
High-dose vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality.
Study context
- Population
- Patients with high-risk CVD (recent acute MI or HF hospitalisation plus ≥1 additional risk factor)of 5260 randomized
- Participants
- 658 patients
- Comparison
- High dose vs Standard dose
- Primary endpoint
- Mean antibody titer change, seroprotection (titer ≥1:40) and seroconversion (≥4-fold titer increase); association of seroconversion with adverse clinical outcomes
- Follow-up
- 4 weeks
Primary result
As reported in the abstract
Antibody response
Seroprotection achieved for each contained antigen by all participants
>92%
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Seroconversion for any antigen and risk of cardiopulmonary hospitalisation or all-cause mortality | 1.09 (0.79–1.53) | P = 0.59 | |
| 0.512Hazard ratio (log scale) |
- Seroconversion for any antigen and risk of cardiopulmonary hospitalisation or all-cause mortality: irrespective of randomized treatment, P = .38 for interaction
Original publication
Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease. JAMA Cardiol. Published 1 June 2024. doi:10.1001/jamacardio.2024.0468
Summarised from the published abstract; every number is checked against it